Hims & Hers Health (HIMS) Projected to Announce Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is projected to release its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $0.0566 per share and revenue of $892.88 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same period last year, the firm earned $0.17 earnings per share. The company’s revenue for the quarter was up 38.2% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post ($0.16) EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

Hims & Hers Health Trading Down 0.3%

Shares of NYSE:HIMS opened at $27.59 on Monday. The stock has a market cap of $6.44 billion, a PE ratio of -43.79 and a beta of 2.53. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $48.34. The business has a 50 day moving average of $29.04 and a 200-day moving average of $27.08.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on HIMS shares. Bank of America increased their price target on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. started coverage on Hims & Hers Health in a research note on Friday, September 11th. They issued a “neutral” rating and a $32.00 price target on the stock. Citigroup decreased their target price on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Three research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $32.43.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah Autor sold 16,773 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $1,363,563.85. This represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This trade represents a 2.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 133,905 shares of company stock worth $3,826,977 in the last three months. Insiders own 11.76% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.